What Микразим Treats: Main Uses and Benefits

Микразим (Mikrazim) is a form of pancreatic enzyme replacement therapy (PERT), which is commonly used to address Exocrine Pancreatic Insufficiency (EPI). This condition is relevant in contexts involving heightened systemic burden.

The therapy is considered relevant for EPI resulting from conditions such as cystic fibrosis, chronic pancreatitis, and pancreatectomy (pancreas removal surgery). The treatment is relevant when supportive symptom management is appropriate and may assist with maintaining functional stability during symptomatic periods.

The treatment provides supportive relief that helps ease the overall symptom burden in clinical settings that involve acute or unstable symptom patterns. This is commonly used across conditions presenting with acute episodes. Enzyme replacement products are applied across domains where additional symptomatic support is needed. This therapy may assist with managing symptoms related to physical discomfort, such as bloating and abdominal pain, as well as conditions where symptoms may intensify temporarily, such as steatorrhea. Enzyme therapy supports patients during episodes of heightened discomfort and contributes to improved comfort during these periods.

---

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

The eligibility for using Микразим (Pancreatin) is strictly defined by government regulatory documents, determining which populations may safely use the medicine and under what conditions.

Contraindications and Exclusions

Classification	Population or Condition
Absolutely Contraindicated	Patients with known hypersensitivity to Pancreatin, porcine proteins, or any excipient [Source 3.6, 3.7].
Use Not Recommended	Patients experiencing acute pancreatitis or an acute exacerbation of chronic pancreatitis [Source 1.2].

Age-Related Eligibility and Restrictions

Микразим is approved for use across the entire lifespan, including adults, older adults, and pediatric patients from infancy [Source 2.1].

• Pediatric Restriction: A critical restriction applies to pediatric patients with Cystic Fibrosis, where the regulatory maximum dose must not be exceeded to prevent the risk of fibrosing colonopathy [Source 2.7, 2.8].

Conditional Use and Special Caution

Regulatory agencies advise caution in the following patient groups, linking eligibility to co-existing medical conditions:

• Patients with Gout or pre-existing Hyperuricemia (high blood uric acid) [Source 2.7].
• Patients with Renal Impairment (Kidney Disease) [Source 2.7].
• Pregnancy and Lactation: Use is permitted only if clearly needed and is considered acceptable during breastfeeding due to the medicine's negligible systemic absorption [Source 2.3, 3.7].

Interactions with other medicines and products

Regulatory documents for Pancreatin products, including Микразим, indicate that the medicine's interaction profile is primarily limited to effects within the gastrointestinal tract due to the active ingredient not being systemically absorbed. This means the medicine does not participate in classic systemic metabolic pathways, such as CYP-enzyme inhibition or induction, and has no documented systemic transporter-based interactions.

Officially documented interactions are focused on local, intraluminal effects:

• Intraluminal Efficacy Reduction: Co-administration with the anti-diabetic medicine Acarbose may reduce its therapeutic effect. This interaction occurs because the amylase component of Pancreatin breaks down the carbohydrate substrate that Acarbose is designed to block, thereby diminishing Acarbose’s mechanism of action.
• Intraluminal Absorption Interference: The product may interfere with the uptake of certain mineral supplements. Specifically, co-administration with Ferrous Iron Salts is documented to result in reduced systemic absorption of iron.

Administration Requirements

The regulatory labeling establishes a mandatory requirement that the medicine be taken with food (a meal or a snack). This is an administration-timing constraint necessary to ensure the digestive enzymes are present in the gut simultaneously with the substrate they are intended to break down. No formal contraindicated combinations based on systemic interaction risk are officially documented.

How Микразим Works — Mechanism of Action

Микразим's action is a specific, non-systemic enzyme replacement mechanism that restores chemical processes essential for nutrient assimilation. The mechanism initiates with enteric-coated microgranules that chemically protect the active enzymes ( Lipase, Amylase, Protease) from gastric acid denaturation. Upon reaching the alkaline environment of the duodenum ( pH > 5.5), the coating dissolves, releasing the high concentration of enzymes at the primary site of digestion.

Once released, the enzymes engage in catalytic hydrolysis, breaking down dietary macronutrients—fats, proteins, and starches—into smaller, absorbable molecular components. Lipase yields fatty acids and monoglycerides; protease yields amino acids; and amylase yields simple sugars. The synergistic action of all three enzyme classes restores the critical, rate-limiting step of intraluminal digestion necessary for the subsequent uptake of molecular components across the intestinal barrier.

This comprehensive breakdown of macronutrients serves a critical physiological function by removing large, osmotically active solutes from the intestinal lumen. The reduction in undigested material influences the osmolality of the intestinal contents, reducing the abnormal fluid dynamics associated with the accumulation of large molecular solutes, thereby regulating the chemical composition of the digestive tract.

Administration of Микразим (Pancreatin) involves specific considerations for timing and dosage integrity. The medication is for oral use, administered in hard capsules containing enteric-coated microgranules.

Administration Principles

The required dose is individualized and calculated primarily based on the patient’s body weight, expressed in Lipase Units (LU) per kilogram per meal. The typical initial starting dosage for adults is approximately 500 LU/kg/meal. The dose generally does not exceed 2,500 LU/kg/meal or 10,000 LU/kg/day.

The medication is taken with every meal and snack to ensure the enzymes are present when food enters the small intestine. The total daily dose is typically divided across approximately three meals and two to three snacks. If a dose is missed, the protocol involves skipping the missed dose and taking the next scheduled dose with the next meal or snack; dose doubling is not performed.

Procedural Conditions

Proper use requires the capsule to be swallowed whole. It is a mandatory procedural constraint that the capsules or their microgranules must not be crushed or chewed, as this action compromises the enteric coating designed to protect the enzymes. For patients who cannot swallow the capsule whole, the contents may be mixed with a small amount of acidic soft food (e.g., applesauce) and consumed immediately. Population-specific protocols exist, such as infants receiving a designated dose of LU per volume of formula or breast milk.

Pancreatin: Recent Clinical Evidence

Микразим is an enzyme preparation where the active component is Pancreatin, a mixture of digestive enzymes (lipase, amylase, and protease) typically derived from porcine sources. It is formulated as enteric-coated pellets (microgranules) to protect the enzymes from inactivation by stomach acid, ensuring they are released and become active in the small intestine.

Efficacy in Exocrine Pancreatic Insufficiency (EPI)

Pancreatic Enzyme Replacement Therapy (PERT) is the standard treatment for Exocrine Pancreatic Insufficiency (EPI), a condition where the pancreas does not produce enough enzymes to properly digest food. EPI is commonly associated with conditions like chronic pancreatitis and cystic fibrosis.

Systematic reviews and meta-analyses of randomized controlled trials (RCTs) confirm the efficacy of PERT in patients with EPI. The primary findings show:

• Improved Nutrient Absorption: PERT significantly enhances the coefficient of fat absorption (CFA) and nitrogen absorption, which reduces steatorrhea (fatty stools) and addresses associated malnutrition.
• Symptom Relief: Studies show an association between PERT use and a reduction in common gastrointestinal symptoms related to maldigestion, such as bloating, gas, and diarrhea.

Safety and Tolerability Profile

Pancreatin formulations are generally considered well-tolerated when used at appropriate doses. Since the enzymes are minimally absorbed into the bloodstream, the risk of systemic side effects is low. The most frequently reported adverse events in clinical trials are mild gastrointestinal disturbances, such as nausea and abdominal discomfort. Rarely, very high doses of pancreatin have been associated with a condition called fibrosing colonopathy.

Key Studies & References

1. Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: A meta-analysis
2. Pancrelipase Therapy - StatPearls [Internet] (Used for Pancreatin composition, indications, and safety)

Common questions about Микразим (FAQ)

---

Q: Is Mikrazim a food supplement or a medicine?

A: According to regulatory documents, Mikrazim is classified as a prescription medicine used for enzyme replacement therapy. It is not considered a dietary supplement, but rather a product subject to official regulatory processes for use in specific medical conditions.

---

Q: What is in Mikrazim besides pancreatin?

A: Official regulatory information, such as the SmPC, includes a list of excipients, or non-active ingredients, used in the formulation. These substances help create the capsule and the enteric-coated microgranules that protect the active pancreatin enzymes.

---

Q: How long must I typically take Mikrazim?

A: Because this medication is indicated for chronic conditions like cystic fibrosis and chronic pancreatitis, official guidance often describes its use as a long-term replacement therapy. Duration of therapy is highly individualized and is established by a healthcare provider based on the patient's condition.

---

Q: Why is Mikrazim supplied as capsules instead of tablets?

A: The medication is formulated in capsules containing enteric-coated microgranules. This specific design is necessary to protect the active enzymes from being destroyed by the strong acid present in the stomach, ensuring they reach the small intestine to be active.

---

Q: Are there age restrictions for Mikrazim use?

A: Official regulatory information contains dosing guidance and specific usage rules tailored for different age groups. This includes population-based dosage rules for infants and specific safety considerations for pediatric patients, particularly those with cystic fibrosis.

---

Q: Can Mikrazim affect blood test results?

A: While the product is non-systemic, meaning it is minimally absorbed into the bloodstream, regulatory documents note rare instances where very high-dose use has been associated with elevated uric acid levels (hyperuricemia).

---

Q: Can I take Mikrazim with other medicines?

A: Official documents describe the drug's interaction profile as primarily limited to effects within the gastrointestinal tract due to its non-systemic nature. Official documentation includes a general requirement that patients inform their healthcare provider about all medicines being taken.

---

Q: Can Mikrazim help with symptoms not listed in its main indications?

A: The medicine is officially indicated only for the treatment of Exocrine Pancreatic Insufficiency (EPI). This means the officially approved use of the product is defined solely by this specific medical condition.

---

Q: Have clinical studies been conducted on children using Mikrazim?

A: Yes, official safety information and regulatory documentation include specific data and warnings related to the use and monitoring of the product in the pediatric population. This information supports official data related to the product's use.

---

Q: Does Mikrazim affect the absorption of vitamins or minerals?

A: Official documents state that the medicine may interfere with the systemic absorption of certain supplements. It specifically lists a potential reduction in the absorption of Ferrous Iron Salts.

---

Q: Is Mikrazim a hormonal drug?

A: No, the product is officially classified as a digestive enzyme replacement medicine. Its mechanism of action is non-systemic, meaning it acts locally in the digestive tract to help break down food, rather than altering hormones in the body.

---

Q: Does Mikrazim contain lactose or gluten?

A: Official regulatory documents require a comprehensive listing of all excipients, or non-active ingredients, used in the final product formulation. Confirmation of the presence or absence of specific components like lactose or gluten relies on this official listing.

---

Q: How quickly can I expect improvement after starting Mikrazim?

A: Clinical studies primarily measure success by observing improvements in nutrient absorption and a reduction in associated gastrointestinal symptoms. These improvements are typically measured over the first few weeks of consistent therapy.

---

Q: Does the effect of Mikrazim last after stopping treatment?

A: The drug functions as a non-systemic enzyme replacement that acts locally within the gastrointestinal tract to aid digestion at the time of the meal. Its effect is temporary, implying no long-lasting or residual therapeutic action after the medicine is stopped.

---

Q: Is it permissible to use Mikrazim during pregnancy?

A: Official labeling addresses use during pregnancy. It indicates that the decision to use the product must be made by a healthcare provider, who is required to weigh the potential benefits of treatment against any possible risks.

---

Q: Can Mikrazim be used while breastfeeding?

A: Regulatory information addresses use while breastfeeding, often noting that it is unknown if the medicine passes into breast milk. The decision regarding use is individualized and is based on a healthcare provider’s professional judgment of the patient’s specific circumstances.

---

Q: Are there known interactions between Mikrazim and alcohol?

A: Official regulatory documents generally contain information regarding the co-administration of the medicine with alcohol. This information necessitates consultation with a healthcare professional regarding consumption of alcohol during treatment.

---

Q: How might Mikrazim interact with acid-reducing medicines (antacids)?

A: Official drug interaction information notes that certain antacids containing calcium or magnesium may reduce the enzyme's effectiveness. This concern is typically addressed by the guidelines on separating the administration times of the two products.

---

Q: Are interactions between Mikrazim and herbal supplements described?

A: Official documents often contain a general requirement that patients disclose the use of all products, including herbal and vitamin supplements, to the healthcare provider, even if specific documented interactions are not listed.

---

Q: Is a doctor's prescription required to buy Mikrazim?

A: According to the medicine's legal classification in many regulatory regions, Mikrazim (pancreatin products) is classified as a prescription-only medicine.

---

Q: What effect does Mikrazim have on body weight?

A: Clinical evidence indicates that the primary function of the drug is to significantly improve nutrient absorption in patients with enzyme deficiency. This action can promote weight gain or stabilization in individuals who are malnourished due to their underlying condition.

---

Q: What are the storage conditions for Mikrazim?

A: Official regulatory information establishes the specific requirements for the temperature and general conditions necessary for the proper storage and handling of the medicine. These instructions are necessary to maintain the integrity and activity of the active enzymes.

---

Q: Why might Mikrazim not be suitable for people with rare hereditary diseases?

A: Official regulatory documents formally contraindicate the medicine in patients who have a known, documented allergy to porcine protein. This is a safety consideration related to the source material of the enzymes.

---

Q: Are there dietary restrictions while taking Mikrazim?

A: Official guidelines specify that the medicine should be taken with every meal and snack to ensure the enzymes are present when food is being digested. Specific restrictions on which types of food to avoid are generally not listed in the official instructions.

---

Q: Can Mikrazim be used by people with diabetes?

A: Official documents highlight a specific potential interaction with the anti-diabetic medicine Acarbose. Due to the documented potential interaction, professional oversight from a healthcare provider is necessary when the drug is used by people with diabetes, especially those taking Acarbose.

---

Q: Is it true that the drug can cause irritation around the anal area?

A: Regulatory safety documents list perianal irritation (burning or itching around the anus) as a possible adverse effect. This is one of the possible adverse effects listed in regulatory safety documents.

How to Store and Dispose of Микразим (Pancreatin)

The official storage conditions for Микразим are designed to protect the integrity of the pancreatic enzymes. The product must be stored in a dry, dark place at a temperature not exceeding 25°C (77°F). It must be kept in its original packaging and stored out of the sight and reach of children.

Stability and Handling

The full labeled shelf-life is maintained only under these conditions. If the product is supplied in a vial, it must be used within six months after first opening the container. Any microgranules mixed with food for administration must be swallowed immediately and not stored.

Disposal

Expired or unused Микразим must not be thrown into household waste or wastewater. The product should be disposed of in accordance with local requirements for pharmaceutical waste.